1. Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments.
- Author
-
Wang, Haojia, Wu, Zhishan, Fan, Xiaotian, Wu, Chao, Lu, Shan, Geng, Libo, Stalin, Antony, Zhu, Yingli, Zhang, Fanqin, Huang, Jiaqi, Liu, Pengyun, Li, Huiying, You, Leiming, and Wu, Jiarui
- Subjects
PANCREATIC tumors ,INJECTIONS ,HIGH performance liquid chromatography ,HERBAL medicine ,IN vivo studies ,XENOGRAFTS ,ANIMAL experimentation ,PHARMACOLOGY ,ANTINEOPLASTIC agents ,HEALTH outcome assessment ,TREATMENT effectiveness ,MASS spectrometry ,TUMOR necrosis factors ,RESEARCH funding ,PHARMACEUTICAL chemistry ,MOLECULAR structure ,VASCULAR endothelial growth factors ,COMPUTER-assisted molecular modeling ,CHINESE medicine ,MICE ,PHARMACODYNAMICS ,DRUG administration ,DRUG dosage - Abstract
Background: Pancreatic cancer is one of the most lethal cancers worldwide. Aidi injection (ADI) is a representative antitumor medication based on Chinese herbal injection, but its antitumor mechanisms are still poorly understood. Materials and methods: In this work, the subcutaneous xenograft model of human pancreatic cancer cell line Panc-1 was established in nude mice to investigate the anticancer effect of ADI in vivo. We then determined the components of ADI using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) and explored the possible molecular mechanisms against pancreatic cancer using network pharmacology. Results: In vivo experiments, the volume, weight, and degree of histological abnormalities of implanted tumors were significantly lower in the medium and high concentration ADI injection groups than in the control group. Network pharmacology analysis identified four active components of ADI and seven key targets, TNF, VEGFA, HSP90AA1, MAPK14, CASP3, P53 and JUN. Molecular docking also revealed high affinity between the active components and the target proteins, including Astragaloside IV to P53 and VEGFA, Ginsenoside Rb1 to CASP3 and Formononetin to JUN. Conclusion: ADI could reduce the growth rate of tumor tissue and alleviate the structural abnormalities in tumor tissue. ADI is predicted to act on VEGFA, P53, CASP3, and JUN in ADI-mediated treatment of pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF